259 related articles for article (PubMed ID: 35680633)
1. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
[No Abstract] [Full Text] [Related]
2. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
[TBL] [Abstract][Full Text] [Related]
4. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
Madan S; Dispenzieri A; Lacy MQ; Buadi F; Hayman SR; Zeldenrust SR; Rajkumar SV; Gertz MA; Kumar SK
Mayo Clin Proc; 2010 Mar; 85(3):232-8. PubMed ID: 20194151
[TBL] [Abstract][Full Text] [Related]
6. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
8. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
9. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
10. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
[TBL] [Abstract][Full Text] [Related]
12. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
[No Abstract] [Full Text] [Related]
13. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
[TBL] [Abstract][Full Text] [Related]
14. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A
Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101
[TBL] [Abstract][Full Text] [Related]
17. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
[TBL] [Abstract][Full Text] [Related]
19. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
20. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
